Tag: atopic dermatitis

Categories : Dermatology PaediatricsTags :

Decoding Baby Eczema and Reassurance for Parents

On By ModernMedia
Photo by William Fortunato

For many South African parents, few things are more stressful than watching their baby’s delicate skin flare up with redness, dryness, or tiny itchy patches. Baby eczema, also called atopic dermatitis, affects up to 1 in 5 children worldwide – and while it’s common, it can leave parents feeling worried and overwhelmed.

But the good news is, with the right skincare routine, baby eczema is manageable. And no, it doesn’t mean your little one will always struggle with sensitive skin.

“Parents are often surprised to learn that baby eczema is not a sign that they’re doing something wrong,” says Karen Van Rensburg, spokesperson for Sanosan South Africa. “It’s a common skin condition linked to an underdeveloped skin barrier, and the key is to protect and strengthen that barrier with gentle care.”

Baby eczema usually shows up between two and six months of age. It can appear on the face, behind the ears, on the arms, legs, or even the chest. The skin becomes dry, red, itchy and, in some cases, scaly.

“Triggers vary,” explains Van Rensburg. “It could be heat, dry air, soaps with harsh ingredients, or even certain fabrics. Understanding what sparks your baby’s flare-ups is an important step in managing the condition.”

So what can parents do at home? Here are some dermatologist-approved tips:

1. Keep baths short and sweet
Stick to lukewarm water and limit bath time to 5–10 minutes. Avoid bubble baths and fragranced soaps.

2. Moisturise immediately after bathing
Lock in hydration by applying a fragrance-free, gentle moisturiser while your baby’s skin is still slightly damp.

3. Choose your products wisely
Opt for creams specifically designed for sensitive baby skin. Look for formulas enriched with natural oils, chamomile, or panthenol – like those found in Sanosan’s baby skincare range.

4. Watch the wardrobe
Dress your baby in soft, breathable cotton and avoid scratchy fabrics like wool. Always wash new clothes before wearing.

5. Spot and soothe flare-ups early
At the first sign of redness or irritation, apply a gentle, protective cream to calm the skin.

6. Don’t overheat the room
Babies with eczema are often sensitive to heat. Keep the nursery cool and use a humidifier if the air feels very dry.

7. See a healthcare professional when needed
If the rash is severe, infected, or your baby seems very uncomfortable, always seek medical advice.

“Parents sometimes think stronger products will ‘fix’ eczema faster,” says Van Rensburg. “But baby skin is incredibly delicate. Harsh ingredients strip away natural oils and make things worse. Gentle, consistent care is far more effective in the long run.”

Baby eczema can feel daunting, but with the right care and patience, most little ones outgrow it as their skin barrier matures. In the meantime, gentle skincare, lots of cuddles, and a watchful eye on triggers can make the world of difference.

“Think of it as supporting your baby’s skin while it learns to protect itself,” Van Rensburg adds. “You’re not just treating eczema – you’re helping build a healthy foundation for life.”

Sanosan focuses on natural ingredients and gentle formulas for healthy skin. Using active ingredients specially tailored to your baby’s skin, natural milk protein is the central ingredient in Sanosan and is especially nourishing. More than 90 % of the ingredients are of natural origin such as organic olive oil, and the formulations are biodegradable.

Safety first: all products are clinically tested and are free from parabens, silicones, paraffins, SLS / SLES and phenoxyethanol. For more info visit sanosan.co.za

Categories : DermatologyTags :

The True Burden of Eczema Goes Beyond the Itch

On By ModernMedia

World Atopic Eczema Day 2025 calls for early intervention, better care, and greater awareness of the hidden toll of atopic dermatitis.

Photo By: Kaboompics.com

On 14 September, people around the world marked World Atopic Eczema Day 2025 under the theme: “Our Skin, Our Journey.” This year’s campaign highlights the lifelong nature of atopic eczema, also known as atopic dermatitis (AD), a disease that usually begins in infancy and can progress to food allergies, asthma and allergic rhinitis.1

“Atopic eczema is more than a skin condition, it is driven by a dysregulated immune system and may have long-term physical and psychological impacts, and creates significant costs for families and healthcare systems,” says Dr Dwayne Koot, pharmacologist and Medical Advisor at Sanofi South Africa.

A disease that begins early

Atopic eczema is one of the most common chronic inflammatory skin diseases, affecting up to 20 percent of children globally.1 It often appears early in life. Around 45 percent of children with atopic eczema develop symptoms before six months of age, 60 percent before one year, and up to 85 percent before five years.1 For many, atopic eczema is the first step in what researchers call the “atopic march,” the progression from skin barrier dysfunction to food allergies and respiratory diseases.2

Studies show that infants with atopic eczema are six times more likely to develop egg allergy and eleven times more likely to develop peanut allergy than infants without atopic eczema.3 By later childhood, as many as 40 percent of children with atopic eczema develop food allergies.2 The condition does not stop there. School-age children with early, persistent atopic eczema face higher risks of developing asthma and allergic rhinitis.4

Beyond the skin

Atopic eczema is now recognised as a systemic disease linked to type 2 inflammation.1 The hallmark symptoms are itching, dry and inflamed skin, recurrent infections and disturbed sleep. These symptoms are not only uncomfortable but also disruptive to daily life.2,5

“Children may struggle at school due to fatigue, and parents often miss work or are unproductive due to sleepless nights, medical appointments or caring for their sick child,” says Dr Koot. “Because atopic eczema is so visible, children often face stigma. Studies show they are more likely to experience anxiety, depression and bullying. Up to one in three children with atopic eczema have anxiety or depression, compared with far fewer children without the disease.”

The economic impact is significant. In South Africa, while direct healthcare costs are relatively low (0,2 percent of healthcare spend), the total burden may be substantial when adding the much higher indirect costs and quality-of-life impacts.6

Why early intervention matters

While research is ongoing, one study found that daily use of emollients from birth to protect the skin barrier may lower the risk of eczema by half for high-risk infants, with no safety concerns.7

Additional research shows that the skin barrier is key in both atopic eczema and food allergies and protecting it early in life may help prevent these conditions.3 While allergen avoidance is still the main approach, new options like immunotherapy and biologics are showing promise.3

Recent findings emphasize that taking early, proactive action with advanced treatments can dramatically improve outcomes for patients, potentially changing the very course of this chronic skin condition.8,9

Traditionally, atopic eczema management has focused on treating symptoms as they arise, especially with topical creams for milder cases.8 However, a deeper understanding of the disease and the development of novel systemic treatments – medications that work throughout the body – reveal a powerful opportunity to intervene much earlier.8 This forward-thinking strategy moves beyond simply reacting to flare-ups; it aims to target the underlying immune imbalance and inflammation that drive eczema from its earliest stages.8

One of the most significant benefits of this early approach is its potential to halt the “atopic march”.9 This refers to the common progression where atopic eczema, often appearing first in infancy or childhood, is followed by other allergic conditions such as food allergies, allergic rhinitis, or asthma.9 By addressing the skin barrier dysfunction and immune system changes early on, we may be able to prevent or reduce the development of these related allergies.9 Studies suggest that allergic sensitization can occur through an impaired skin barrier, and early treatment of this dysfunction could serve as a preventive strategy for food allergy progression.9

Furthermore, early intervention is key to breaking the relentless “itch-scratch cycle”.8 Chronic itching, a hallmark of atopic eczema, not only causes immense discomfort but also leads to skin damage and secondary complications like infections. 8 By addressing the root causes of itching, patients can experience comprehensive relief, regain normalcy, and significantly improve their overall quality of life, sleep, and mental well-being by reducing anxiety, depression, and social isolation associated with the disease.8

This proactive strategy also offers the promise of long-term disease control and modification.8 By tackling inflammation before visible skin lesions fully develop, it can inhibit the escalation of inflammatory responses and disrupt the recurring cycles of flares and remissions.8  

“The paradigm shift towards early systemic intervention represents a pivotal moment in atopic eczema care,” says Dr. Koot. “It’s about empowering patients with strategies that offer not just immediate relief, but also the potential for sustained positive outcomes and a better quality of life by addressing the disease at its inception, rather than solely managing its symptoms after they become severe.”

Working together

“World Atopic Eczema Day 2025 is a call to action,” says Dr Koot. “Doctors need to see atopic eczema as a systemic disease that needs more than just symptom relief. Policymakers need to support early treatment, better access to specialist care, affordable medicines, and stronger investment in research and innovation. Families and patient groups play a key role in showing the true impact of atopic eczema and pushing for advanced, targeted therapies.”

The campaign also recognises the importance of community. Social media initiatives such as #AtopicEczemaJourney give patients and families a space to share their stories, connect with others and draw attention to the reality of living with atopic eczema.

“Progress is possible, but it requires commitment from everyone,” says Dr Koot. “Research shows that simple measures, such as protecting infant skin with frequent use of emollients and avoiding triggers, can drastically improve control of atopic eczema. Public health strategies, better access to care, early intervention and investment in new treatments all make a difference. At the same time, society needs to understand that atopic eczema is not only about rashes or itching. It is a systemic, lifelong condition that affects education, careers, relationships and quality of life.”

Categories : DermatologyTags :

Long-Term Atopic Dermatitis Treatment Benefits Patients with Delayed Response

On By ModernMedia
Atopic dermatitis in a young patient. Source: NIH

New research from the Icahn School of Medicine at Mount Sinai reveals that patients with moderate-to-severe atopic dermatitis (eczema) who did not initially respond to biologic treatment may still achieve significant clinical improvements with continued therapy.  

The findings, published in the latest issue of Journal of the American Academy of Dermatology (JAAD), highlight the efficacy of extended lebrikizumab treatment up to 52 weeks and pave the way for more personalised, patient-centred approaches to managing this chronic skin condition. 

Lebrikizumab is designed to treat moderate-to-severe eczema by targeting a key source of inflammation in the body. It works by blocking interleukin-13 (IL-13), a protein that plays a central role in the itching, redness, and skin damage seen in atopic dermatitis. 

“This is a significant breakthrough because it shows that people who do not respond to lebrikizumab treatment right away should not give up,” says lead author Professor Emma Guttman-Yassky, MD, PhD, at Mount Sinai. “Initial non-response at 16 weeks does not mean treatment failure. By sticking with treatment longer (52 weeks), most patients saw their eczema improve significantly.” 

Researchers analysed data from two international clinical trials. At 16 weeks, 38.1% of lebrikizumab-treated patients failed to meet strict trial criteria for response. However, 58.1% had already achieved at least a 50% improvement in their Eczema Area and Severity Index (EASI) scores. By 52 weeks, 75.5% had reached a 75% improvement (EASI 75), 44.2% had achieved a 90% improvement (EASI 90), and 66.4% reported a significant reduction in itching. 

“This research supports a more personalised approach to care,” Dr. Guttman-Yassky says. “It offers new hope for patients with difficult-to-treat eczema and may help guide treatment decisions in clinical practice.” 

Source: Mount Sinai Hospital

Categories : DermatologyTags :

Survey Sheds Light on the Phenomenon of Topical Steroid Withdrawal

On By ModernMedia
Source: Pixabay

Painful skin and trouble sleeping are among the problems reported when tapering cortisone cream for atopic eczema, as shown by a study headed by the University of Gothenburg. Many users consider the problems to be caused by cortisone dependence.

Topical steroid withdrawal (TSW) is a phenomenon commonly described as extremely red and painful skin arising when cortisone cream treatment is tapered or stopped.

While TSW is not an established diagnosis, the name indicates that the skin has become dependent on cortisone. Little research has been conducted to identify a dependency mechanism, so scientific support is lacking. At the same time, the term has become commonplace on social media, raising concerns among patients about cortisone cream safety.

Now, a national research group in Sweden, headed by Sahlgrenska Academy at the University of Gothenburg, has conducted the first study in which a larger group has been asked to provide a detailed account of what they consider to be TSW. The results are published in the journal Acta Dermato-Venereologica.

Questionnaire via social media

The study targeted adults with atopic eczema, a group that often uses cortisone cream, who also identified as suffering from TSW. The study was conducted by means of an anonymous questionnaire presented in Swedish in social media forums, with the option to share a link to invite other potential participants. The questionnaire was answered by almost one hundred people aged 18–39, the majority of whom were women.

“We wanted to gain more knowledge about how those who identify as suffering from TSW define the phenomenon and which symptoms they describe,” says Mikael Alsterholm, a researcher at the University of Gothenburg and a senior consultant in dermatology and venereology at Sahlgrenska University Hospital.

The results show variations in how the participants defined TSW. Most common was to define it as a dependence on cortisone, with symptoms arising when tapering or stopping its use, although many others also defined TSW as a reaction to cortisone already during its use.

It was also common to define TSW on the basis of the symptoms seen in the skin, such as redness and pain. While the symptoms described varied, they were largely similar to the symptoms seen in an exacerbation of atopic eczema.

In addition to the skin becoming red, dry, and blistered – mainly on the face, neck, torso, and arms – the participants also described sleep problems due to itching as well as signs of anxiety and depression.

Healthcare and research involvement

A majority of the participants described concurrent symptoms of both atopic eczema and TSW. Cortisone cream was most often cited as the triggering factor, while some cited cortisone tablets and a few cortisone-free treatments.

“It’s important that healthcare professionals and researchers are involved in the discussion on TSW and contribute science-based knowledge where possible. Cortisone cream is an effective and safe treatment for most people, and at present there’s no support for avoiding its use for fear of the types of symptoms described in the context of TSW,” says Mikael Alsterholm.

“At the same time, there’s a patient group with different experiences, expressed as TSW, and their symptoms and the potential causes need to be investigated by means of both research and practical healthcare. To do this, we first need to define TSW. While we understand that this is complicated, we hope that this study can help establish such a definition,” he concludes.

Source: University of Gothenburg

Categories : Dermatology Environmental EffectsTags :

Air Pollution Exposure may be Associated with Eczema

On By ModernMedia

Data from hundreds of thousands of U.S. adults suggests that each zip code increase of 10 µm/m3 in PM2.5 levels is associated with a doubling in eczema rates among residents

Photo by Kouji Tsuru on Pexels

People living in areas with higher levels of air pollution are more likely to have eczema, according to a new study published November 13, 2024 in the open-access journal PLOS ONE by Dr Jeffrey Cohen of Yale School of Medicine, USA.

The prevalence of eczema has increased globally with industrialisation, suggesting a possible contribution from environmental factors. In the new study, researchers used data from the U.S. National Institutes of Health All of Us Research Program, covering hundreds of thousands of U.S. adults. The current study included 286 862 people for whom there was available demographic, zip code and electronic health record data.

Overall, 12 695 participants (4.4%) were diagnosed with eczema. After controlling for demographics and smoking status, people with eczema were more likely to live in zip codes with high levels of fine particulate matter, or PM2.5, in the air. For every increase of 10 µm/m3 in average PM2.5 air pollution in their zip code, people were more than twice as likely to have eczema.

The authors conclude that increased air pollution, as measured by PM2.5, may influence the risk of developing eczema, likely through its effects on the immune system.

The authors add: “Showing that individuals in the United States who are exposed to particulate matter are more likely to have eczema deepens our understanding of the important health implications of ambient air pollution.”

Provided by PLOS

Categories : DermatologyTags :

Linked Biological Pathways Drive Skin Inflammation

On By ModernMedia
Picture by Macrovector on Freepik

A certain biological pathway involving interleukin-17 drives the inflammation seen in the skin disease psoriasis, according to a new study published in the journal Immunity. The work could lead to improved therapies for all inflammatory skin diseases, including atopic and allergic dermatitis and a type of boil called hidradenitis suppurativa, say the study authors.

Led by researchers at NYU Langone Health, the new study found that the interleukin-17 (IL-17) pathway, whose activity is blocked by existing anti-inflammatory drugs, activates a protein called hypoxia inducible factor 1-alpha (HIF-1-alpha) in psoriasis. Researchers say that IL-17 has long been known to be active in inflammation, but the role of HIF-1-alpha has until now been unclear.

The research team also found that HIF-1-alpha let inflamed skin cells more actively break down sugar for energy, supporting their metabolism and leading to the production of a waste product called lactate. When consumed by inflammatory T cells, lactate triggered production of IL-17, fuelling even more inflammation.

The findings show that in human skin tissue samples from psoriatic patients, measures of gene activity around IL-17 and HIF-1-alpha were similar, suggesting that these factors are interconnected. Experiments in mice treated to develop psoriasis found that subsequent treatment with an experimental drug that blocks the action of HIF-1-alpha, called BAY-87-2243, resolved inflammatory skin lesions.

Further, skin samples from 10 patients successfully treated with anti-inflammatory drug etanercept showed diminished activity for both IL-17 and HIF-1-alpha, suggesting to researchers that when IL-17 is blocked, so is HIF-1-alpha.

“Our study results broadly show that activation of HIF-1-alpha is at the crux of metabolic dysfunction observed in psoriasis and that its action is triggered by IL-17, another key inflammatory-signaling molecule,” said corresponding study author Shruti Naik, PhD, associate professor at NYU Grossman School of Medicine.

Further experiments were performed on skin samples from five patients with psoriasis whose healthy and inflamed skin was separately treated with either BAY-87-2243 or an existing combination of topical drugs (calcipotriene and betamethasone dipropionate). Researchers then compared differences in inflammatory gene activity as a measure of impact and found that the HIF-1-alpha inhibitor had a greater effect than existing topical drugs. Specifically, skin samples that responded to HIF-1-alpha therapy had 2,698 genes that were expressed differently, while standard-of-care-treated samples had 147 differently expressed genes.

Genetic analysis of skin samples from another 24 psoriatic patients treated with the IL-17A-blocking drug secukinumab showed only decreased, not heightened, gene activity connected to HIF-1-alpha when compared to HIF-1-alpha gene activity in nine healthy patients with no psoriatic disease. Researchers say this indicates HIF-1-alpha’s blocked action was codependent on blockage of IL-17.

Additional experiments in mice showed that blocking glucose uptake in the skin slowed psoriatic disease growth by limiting glucose metabolism, or glycolysis. Both the number of immune T cells tied to inflammation and the cell levels of IL-17 also decreased. The researchers found further that levels of lactate, the main byproduct of glycolysis, in psoriatic skin cell cultures dropped once exposed to the glycolysis-inhibiting drug 2-DG.

Directly targeting lactate production in psoriatic mice using a topical skin cream containing lactate dehydrogenase, which breaks down lactate, also slowed disease progression in the skin, with reduced numbers of inflammatory gamma-delta T cells and reduced IL-17 activity. Gamma-delta T cells were shown to take up lactate and use it to produce IL-17.

“Evidence of HIF-1-alpha’s depressed action, or downregulation, could also serve as a biomarker, or molecular sign, that other anti-inflammatory therapies are working,” said study co-senior investigator Jose U. Scher, MD, professor at NYU Grossman School of Medicine.

Scher, who also serves as director of NYU Langone’s Psoriatic Arthritis Center and the Judith and Stewart Colton Center for Autoimmunity, says the team plans to develop experimental drugs that can block HIF-1-alpha and lactate action in the skin “to end the underlying vicious cycle of IL-17-driven inflammation in skin disease. Our research fundamentally expands the scope of feasible therapeutic options.”

Naik points out that while many available therapies for psoriasis, including steroids and immunosuppressive drugs, reduce inflammation and symptoms, they do not cure the disease. She said further experiments are needed to refine which experimental drug works best, with respect to HIA-1-alpha inhibition, before clinical trials could start.

Source: NYU Langone Health / NYU Grossman School of Medicine

Categories : Dermatology Immune SystemTags :

When This Itch Cytokine ‘Talks’, Neurons Respond

On By ModernMedia
Photo by FOX

Scratching an itch can be a relief, but for many patients it can get out of control, becoming a serious health problem. So what normally stops this progression?

A paper published in Science Immunology reports a breakthrough that could transform how doctors treat conditions from atopic dermatitis to allergies, they have discovered a feedback loop centred on a single immune protein called IL-31 that both causes the urge to itch and dials back nearby inflammation.

The findings, by Scientists at UC San Francisco, lay the groundwork for a new generation of drugs that interact more intelligently with the body’s innate ability to self-regulate.

Previous approaches suggested that IL-31 signals itch and promotes skin inflammation. But the UCSF team discovered that nerve cells, or neurons, that respond to IL-31, triggering a scratch, also prevent immune cells from overreacting and causing more widespread irritation.

“We tend to think that immune proteins like IL-31 help immune cells talk to one another, but here, when IL-31 talks to neurons, the neurons talk right back,” said Marlys Fassett, MD, PhD, UCSF professor of dermatology and lead author of the study. “It’s the first time we’ve seen the nervous system directly tamp down an allergic response.”

The discovery could eventually change how asthma, Crohn’s and other inflammatory diseases are treated, due to IL-31’s presence throughout the body.

“IL-31 causes itch in the skin, but it’s also in the lung and in the gut,” said Mark Ansel, Ph.D., UCSF professor of immunology and senior author of the study. “We now have a new lead for fighting the many diseases involving both the immune and nervous systems.”

More than an itch

IL-31 is one of several “itch cytokines” because of its ability to instigate itch in animals and people. Fassett, a dermatologist and a researcher, has wanted to know why since she arrived at UCSF in 2012, a few years after its discovery. She reached out to Ansel, a former colleague and asthma expert who welcomed her into his lab.

First, Fassett removed the IL-31 gene from mice and exposed them to the house dust mite, a common, itchy allergen.

“We wanted to mimic what was actually happening in people who are chronically exposed to environmental allergens,” Fassett said. “As we expected, the dust mite didn’t cause itching in the absence of IL-31, but we were surprised to see that inflammation went up.”

Why was there inflammation but no itching? Fassett and Ansel found that a cadre of immune cells had been called into action in the absence of the itch cytokine. Without IL-31, the body was blindly waging an immunological war.

IL-31 brings balance to the forces

Ansel and Fassett then homed in on the nerve cells in the skin that received the IL-31 signal. They saw that the same nerve cells that spurred a scratch also dampened any subsequent immune response. These nerve cells were integral to keeping inflammation in check, but without IL-31, they let the immune system run wild.

The findings squared well with what dermatologists were increasingly seeing with a new drug, nemolizumab, which blocked IL-31 and was developed to treat eczema. While clinical trial patients found that the dry, patchy skin of their eczema receded on the drug, other skin irritation, and even inflammation in the lungs, would sometimes flare up.

“When you give a drug that blocks the IL-31 receptor throughout the whole body, now you’re changing that feedback system, releasing the brakes on allergic reactions everywhere,” Ansel said.

Fassett and Ansel also found that these neurons released their own signal, called CGRP, in response to the itch signal, which could be responsible for dampening the immune response.

“The idea that our nerves contribute to allergy in different tissues is game changing,” Fassett said. “If we can develop drugs that work around these systems, we can really help those patients that get worse flares after treatment for itch.”

Fassett recently founded her own lab at UCSF to tease apart these paradoxes in biology that complicate good outcomes in the clinic. And Ansel is now interested in what this itch cytokine is doing beyond the skin.

“You don’t itch in your lungs, so the question is, what is IL-31 doing there, or in the gut?” Ansel asked. “But it does seem to have an effect on allergic inflammation in the lung. There’s a lot of science ahead for us, with immense potential to improve therapies.”

Source:

Categories : Diseases, Syndromes and Conditions PaediatricsTags :

Strong Results from Methotrexate Trial for Severe Atopic Dermatitis in Kids

On By ModernMedia
Atopic dermatitis in a young patient. Source: NIH

Positive results from a clinical trial comparing the safety and efficacy of ciclosporin with methotrexate in children and adolescents with severe dermatitis will likely change treatment paradigms for this debilitating skin condition, its researchers have said. The trial, published in the British Journal of Dermatology, also examined whether the severity of the disease changed or returned after treatment ended.

For children and young people with atopic dermatitis, the most common skin condition in children, the main first line conventional systemic treatments are methotrexate and ciclosporin, two immuno-modulatory drugs.

There have been no adequately powered randomised clinical trial evidence for safety and treatment success for paediatric patients with this condition, and with new therapies being introduced at a high cost, establishing a gold standard for treatment with the conventional systemic therapies like methotrexate and ciclosporin is needed.

The trial, led by King’s College London, assessed 103 children with severe atopic dermatitis age 2–16 years across 13 centres in the UK and Ireland. The patients were given oral doses of methotrexate or ciclosporin and assessed over nine months of treatment and six months after the therapy ended.

The study found that ciclosporin works faster and reduces disease severity more at 12 weeks but was more expensive, whereas methotrexate was significantly cheaper and led to better objective disease control after 12 weeks and off therapy, with fewer participant-reported flares of atopic dermatitis after treatment had stopped. There were also no concerning safety signals.

Based on the TREAT trial findings, methotrexate is a useful and safe treatment in paediatric patients with severe atopic dermatitis and a good alternative to ciclosporin, especially in settings where health care resources are limited.

Professor Carsten Flohr, Chair in Dermatology and Population Health Sciences at King’s College London, and consultant dermatologist at St John’s institute of dermatology, Guy’s and St Thomas’ NHS Foundation Trust, said:

“This is the largest paediatric trial using conventional immuno-modulatory treatments in severe atopic dermatitis and was conducted across 13 centres in the UK and Ireland and is likely to change our treatment paradigm around this condition, not just for patients in the UK but also internationally.”

Source: King’s College London

Categories : Gastrointestinal Immune SystemTags :

Atopic Dermatitis Increases Risk of New-onset IBD

On By ModernMedia
Source: CC0

Adults with atopic dermatitis (AD) have a 34% increased risk of developing new-onset inflammatory bowel disease (IBD) compared to those without the skin condition, according to a new recently published in JAMA Dermatology. The study also shows for children, the risk increase is 44%. Additionally, as the severity of AD increased, the risk of developing IBD rose.

These findings clear up ambiguity from previous research, especially among populations of children and between the different types of IBD: ulcerative colitis and Crohn’s disease. While IBD is located in the gut and AD affects the skin, both diseases are driven by the immune system and are categorised by severe inflammation. Insight offered from this study from the Perelman School of Medicine at the University of Pennsylvania could lead to new treatments for both IBD and AD.

“It is imperative for clinicians to understand atopic dermatitis and the trajectory of our patients with it in order to provide the best standard of care,” said senior author Joel M Gelfand, MD, dermatology professor at Penn. “There are new and better treatments for AD today, and there will likely continue to be more. But providers have to understand how those treatments could impact other autoimmune diseases. For patients with AD and another autoimmune disease, some currently available medications can exacerbate symptoms of their other disease or can help treat two immune diseases at the same time.”

While this is not the first study to explore AD and IBD, its size, with one million adult and child participants with AD drawn from a UK medical database, and its separation between ulcerative colitis and Crohn’s disease advances previous research.

When looking at ulcerative colitis and Crohn’s disease separately, AD was not linked to higher ulcerative colitis in children unless the kids had severe AD. Children with AD, however, had a 54–97% increased relative risk of Crohn’s disease, and among children with severe AD, their risk was roughly five times higher. Results among adults were more straightforward. Adults with AD had a 32% increased relative risk of ulcerative colitis and a 36% increased relative risk of Crohn’s disease. Gelfand notes that the absolute extra risk of developing IBD in individuals with AD is still quite small, but the association is meaningful in better understanding health outcomes in AD. Moreover, since millions of people have AD, this small increase in risk spread among many people is likely important from a public health perspective.

Although Penn researchers did not look at the root cause of IBD linked to AD, they have strong hypotheses about the links.

“AD and IBD can cause changes in the microbiome, chronic inflammation, and the dysfunction in the skin and gut barrier respectively,” said Gelfand, who is also the director of the Center for Clinical Sciences in Dermatology at Penn. “There are also specific cytokines, certain kinds of proteins, that play a role in immune system activity and that seem to be related to AD and IBD. For example, we think dysfunction of types of T cells common to both AD and IBD, could be the culprits. Those need to be explored further to uncover both what’s happening at a microscopic level and what proteins or structures could be targeted to treat one or both conditions.”

As a leading expert on psoriasis, a disease known to be tied to IBD genetically, Gelfand is well aware of how closely skin health can affect other parts of the body. He and his colleagues are also studying AD’s relationship to infections, neurologic and psychiatric disorders, and cardiovascular disease.

“Investigating the relationship between skin diseases and other diseases doesn’t just offer new insight into how these diseases can affect a patient with both, but these studies are especially powerful because they also highlight unique characteristics of each disease and how they behave individually,” Gelfand shared.

Source: University of Pennsylvania School of Medicine

Categories : PaediatricsTags :

Some Countries Have a Substantial Burden of Eczema in Youth

On By ModernMedia
Atopic dermatitis
Source: Wikimedia CC0

New research published in Clinical & Experimental Allergy indicates that the burden related to eczema in young individuals is substantial in a number of countries. A median of 6% of both children and adolescents experience some form of eczema while 0.6% and 1.1% of children and adolescents, respectively, report symptoms of severe eczema. 

The results come from an analysis of data from 14 countries involving 74 361 adolescents aged 13–14 years and 47 907 children aged 6–7 years. 

Investigators estimated an average increase over 27 years in the prevalence of current eczema symptoms of 0.98% per decade in adolescents and 1.21% per decade in children, and of 0.26% and 0.23% per decade in severe eczema symptoms. However, there was substantial variation in changes in eczema prevalence over time by income and region.

“Eczema remains a big public health problem around the world,” said corresponding author Sinéad Langan, PhD, of the London School of Hygiene & Tropical Medicine. “Global research efforts are needed to address the burden related to eczema with continued international efforts to identify strategies to prevent the onset of eczema and to better manage the impact on individuals, their families, and health service.”

Source: Wiley